Showing 1 - 4 results of 4 for search 'Sarah-Katharina Kays', query time: 0.03s Refine Results
  1. 1
    A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

    A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant by Olaf-Oliver Wolz, Sarah-Katharina Kays, Helga Junker, Sven D. Koch, Philipp Mann, Gianluca Quintini, Philipp von Eisenhart-Rothe, Lidia Oostvogels

    Published 2022-03-01
    Get full text
    Article
  2. 2
    Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective

    Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective by Dina Kleinlützum, Dina Kleinlützum, Dina Kleinlützum, Julia D. S. Hanauer, Alexander Muik, Kay-Martin Hanschmann, Sarah-Katharina Kays, Camilo Ayala-Breton, Kah-Whye Peng, Michael D. Mühlebach, Tobias Abel, Christian J. Buchholz, Christian J. Buchholz

    Published 2017-06-01
    Get full text
    Article
  3. 3
    Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

    Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] by Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study

    Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study by Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels

    Published 2022-08-01
    Get full text
    Article

Search Tools: